Topline data expected as early as Q1 2024OCALA, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American:…
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer…
State-of-the-art facility will expand preclinical, clinical and process development capabilities to advance the company’s pipeline of innovative gamma-delta T cell…
SBS-518 is a dual sigma receptor antagonist/dopamine active transporter inhibitor in development for the treatment of stimulant use disorder (e.g.,…
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in…
BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…
- Initiated dosing at U.S. sites for VIRAGE, the Phase 2b clinical trial of VCN-01 in combination with chemotherapy for…
Organization fully focused on product candidates and collaborations based on next-generation ADC platformsCapital resources expected to support current operating plan…
Recursion's Pipeline Recursion's internal pipeline as of Q2 2023Deployed new digital chemistry technology, together with NVIDIA, to predict the ligand-protein…
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc.…